HKD 3.58
(-0.56%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 77.54 Million USD | -14.93% |
2022 | 91.15 Million USD | 32.27% |
2021 | 68.91 Million USD | 237.66% |
2020 | 20.4 Million USD | 38.97% |
2019 | 14.68 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 FY | 85.36 Million USD | -6.36% |
2023 Q1 | - HKD | 0.0% |
2023 Q2 | - HKD | 0.0% |
2023 Q3 | - HKD | 0.0% |
2022 FY | 91.15 Million USD | 32.27% |
2022 Q4 | - HKD | 0.0% |
2022 Q3 | - HKD | 0.0% |
2021 Q3 | 15.01 Million USD | 0.0% |
2021 Q4 | 32.88 Million USD | 119.0% |
2021 FY | 68.91 Million USD | 237.66% |
2020 Q4 | 6.96 Million USD | 0.0% |
2020 FY | 20.4 Million USD | 38.97% |
2019 FY | 14.68 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Uni-Bio Science Group Limited | 325.05 Million HKD | 76.144% |
CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 89.511% |